Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
The company will work with researchers at UCSD's Moores Cancer Center on two studies of patients with breast, lung, and colon cancers.
The company will supply the Chinese laboratory with its ClearCell FX1 system and help train and assist its new partner in developing cancer tests.
Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.
The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.
Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
The method uses hydrogel encapsulation, which mimics a tissue sample, in order to allow circulating tumor cell isolation and extraction through laser dissection.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.